Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073866 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00073866: Completed Phase 1 study, sponsored by Northwestern University.
NCT00073866 is a Phase 1 study that has completed, run by Northwestern University. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00073866, a Phase 1 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor. Combining celecoxib with combination chemotherapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of irinotecan and docetaxel when given together with celecoxib and to see how well they work in treating patients with advanced non-small cell lung cancer.
Interventions
- DRUG docetaxel
- DRUG irinotecan hydrochloride
- DRUG celecoxib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-06 |
| Est. Completion | 2004-12 |
| Phase | Phase 1 |
What the finished NCT00073866 record still lists
NCT00073866 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which docetaxel is the first listed.
NCT00073866 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00073866 about?
NCT00073866 is a clinical study titled "Combination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor. Combining celecoxib with combination chemotherapy may kill more tumor cells. PURPOSE: This phase ...
What is the current status of trial NCT00073866?
This trial is currently completed. It is a Phase 1 study. The study started on 2003-06. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00073866?
The interventions under investigation include: docetaxel (DRUG), irinotecan hydrochloride (DRUG), celecoxib (DRUG).
Who is sponsoring clinical trial NCT00073866?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia